EA201890346A1 - Ингибитор pdf4 для лечения диабетической нефропатии - Google Patents

Ингибитор pdf4 для лечения диабетической нефропатии

Info

Publication number
EA201890346A1
EA201890346A1 EA201890346A EA201890346A EA201890346A1 EA 201890346 A1 EA201890346 A1 EA 201890346A1 EA 201890346 A EA201890346 A EA 201890346A EA 201890346 A EA201890346 A EA 201890346A EA 201890346 A1 EA201890346 A1 EA 201890346A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
treatment
pdf4
diabetic
phosphodiesterase
Prior art date
Application number
EA201890346A
Other languages
English (en)
Russian (ru)
Inventor
Гвидо ХАНАУЭР
Штефани Фоллерт
Масатоси Хадзама
Таканори Мацуо
Original Assignee
Такеда Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Гмбх filed Critical Такеда Гмбх
Publication of EA201890346A1 publication Critical patent/EA201890346A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201890346A 2015-07-29 2016-07-28 Ингибитор pdf4 для лечения диабетической нефропатии EA201890346A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29
PCT/EP2016/067968 WO2017017165A1 (en) 2015-07-29 2016-07-28 Pde4 inhibitor for the treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
EA201890346A1 true EA201890346A1 (ru) 2018-08-31

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890346A EA201890346A1 (ru) 2015-07-29 2016-07-28 Ингибитор pdf4 для лечения диабетической нефропатии

Country Status (9)

Country Link
US (1) US20200179369A1 (enExample)
EP (1) EP3328381A1 (enExample)
JP (1) JP2018521077A (enExample)
CN (1) CN108135886A (enExample)
BR (1) BR112018001116A2 (enExample)
CA (1) CA2992796A1 (enExample)
EA (1) EA201890346A1 (enExample)
MA (1) MA42519A (enExample)
WO (1) WO2017017165A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179384B2 (en) 2016-08-26 2021-11-23 Takeda Gmbh Treatment of nonalcoholic fatty liver disease
CN107157999A (zh) * 2017-05-27 2017-09-15 青岛海蓝医药有限公司 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
CN114053281B (zh) * 2020-08-10 2025-05-27 成都文鼎科技发展有限公司 治疗慢性肾病的方法和药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413751B2 (en) * 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
EP2589599B1 (en) * 2004-03-03 2014-06-25 Takeda GmbH Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method

Also Published As

Publication number Publication date
JP2018521077A (ja) 2018-08-02
CA2992796A1 (en) 2017-02-02
EP3328381A1 (en) 2018-06-06
WO2017017165A1 (en) 2017-02-02
BR112018001116A2 (pt) 2018-09-11
US20200179369A1 (en) 2020-06-11
CN108135886A (zh) 2018-06-08
MA42519A (fr) 2018-06-06

Similar Documents

Publication Publication Date Title
EP3850110A4 (en) MODIFIED ARCHAEAL POLYMERASES OF THE B FAMILY
IL280593A (en) Pyrrolopyrimidine itk inhibitors
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
CL2020000173S1 (es) Masajeador.
MX377710B (es) Anticuerpos monoclonales contra bcma.
EA201892581A1 (ru) Варианты комбинированной терапии ингибиторами hdac и ингибиторами pd-l1
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
CL2016002731A1 (es) Herbicidas de piridazinona
CA2939010C (en) Tissue factor pathway inhibitor antibodies
EP3723650A4 (en) MEDICAL TOOLS WITH DRAWBARS
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
DK3624796T3 (da) Pyrrolopyridin.anilinforbindelser til behandling af hudlidelse
CL2018000290A1 (es) Antagonistas del receptor de cgrp
LT3506900T (lt) Ampreloksetinas, skirtas naudoti neurogeninės ortostatinės hipotenzijos gydymui
EA201890346A1 (ru) Ингибитор pdf4 для лечения диабетической нефропатии
EA201790373A1 (ru) Способы получения модуляторов toll-подобных рецепторов
EP3635047A4 (en) AMORPHIC COPOLYMERS OF PROPYLENE-ETHYLENE
DK3516723T3 (da) Elektrokemisk direkte varme-til-elektricitetsomformer
PE20180503A1 (es) 2-tiopirimidinonas